Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 12, 2020 | Series B | $21M | 1 | — | — | Detail |
Oct 22, 2019 | Series A | $6M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Time Folio Asset Management | — | Series B |